Synthon and MIVAC Development enter into exclusive research collaboration and commercial licensing agreement in multiple sclerosis

03-Jun-2011 - Netherlands

Synthon and MIVAC Development announced that they have entered into a new, exclusive and broad ranging research and development collaboration to produce innovative treatments for patients with multiple sclerosis.

The collaboration will combine Synthon’s expertise in the pharmaceutical arena and business acumen with MIVAC Development’s tolerance-inducing fusion protein technology.

Under the collaboration, Synthon and MIVAC Development will create multiple new therapeutic candidates, research and screen these to identify novel lead compounds which Synthon will develop further into the clinic and bring onto the market.
The result of this collaboration could be a new treatment paradigm for multiple sclerosis patients offering superior efficacy with greater ease of use and improved tolerability.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances